CHRONIC LYMPHOCYTIC LEUKAEMIA: CALL FOR ABSTRACTS #ESHCLL2022

ESH 2nd Translational Research Conference
CHRONIC LYMPHOCYTIC LEUKAEMIA

March 18-20, 2022
Paris, France
#ESHCLL2022

---

CALL FOR ABSTRACTS!
DEADLINE: JANUARY 9th, 2022

Abstracts are eligible to be selected
for an oral or a poster presentation.

---

REGISTRATION IS OPEN
Join us in Paris!

---

About the Conference:

The 2nd ESH TRANSLATIONAL RESEARCH CONFERENCE ON CHRONIC LYMPHOCYTIC LEUKAEMIA can now be held in person to achieve again scientific interactions that are the primary goal of our gathering. The Conference is proposing a programme of leading-edge basic and clinical science where a panel of global experts in the field will provide numerous opportunities for formal and informal interactions to discuss the present and the future of CL research. It is open to an international audience of biologists and clinicians, particualry welcoming those in-training.

This translational research conference will explore the most recent advances in the understanding of the pathogenesis and clinical management of the disease. Open and spirited discussion on the most up-to-date information in the field is expected to understand how all the new insights to the future of CLL.

For more information, click here!

---

CONFERENCE MAIN TOPICS:

• Spectrum of CLL disease: MBL to Richter’s transformation
• New insights in “old” biomarkers
• Taking driver gene mutations to the next level
• Beyond BcR: other microenvironmental stimuli
• Time-limited therapy
• Covalent BTK inhibitors
• BTK and Bcl2 inhibitor resistance
• Next generation therapies
• The future: other targets

---

LEARNING OBJECTIVES:
Upon completion of this CME activity, participants should be able to:
• Understand recent advances in elucidating the pathogenesis of CLL
• Describe recent data on the use of prognostic/predictive factors
• Become familiar with the decision-making process for the novel therapeutics for CLL
• Understand emerging data on mechanisms of resistance to targeted agents in CLL
• Understand the debate about how best to optimize CLL therapy in the future